PubRank

Dorothee von Laer

Author PubWeight™ 44.00‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Endoproteolytic processing of the lymphocytic choriomeningitis virus glycoprotein by the subtilase SKI-1/S1P. J Virol 2003 2.57
2 Resistance of mature T cells to oncogene transformation. Blood 2008 2.32
3 Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range. J Virol 2002 1.74
4 Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 2007 1.44
5 Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 2004 1.43
6 CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica 2010 1.30
7 Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene. Mol Ther 2007 1.29
8 Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. PLoS One 2009 1.19
9 A-to-G hypermutation in the genome of lymphocytic choriomeningitis virus. J Virol 2006 1.18
10 Predictable and efficient retroviral gene transfer into murine bone marrow repopulating cells using a defined vector dose. Exp Hematol 2003 1.16
11 Age-matched lymphocyte subpopulation reference values in childhood and adolescence: application of exponential regression analysis. Eur J Haematol 2008 1.15
12 Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol 2011 1.06
13 Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010 1.06
14 Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 2005 1.06
15 Membrane-anchored inhibitory peptides capture human immunodeficiency virus type 1 gp41 conformations that engage the target membrane prior to fusion. J Virol 2006 1.03
16 Retroviral vectors pseudotyped with severe acute respiratory syndrome coronavirus S protein. J Virol 2004 1.03
17 An improved bicistronic CD20/tCD34 vector for efficient purification and in vivo depletion of gene-modified T cells for adoptive immunotherapy. Mol Ther 2010 1.00
18 Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS One 2010 0.99
19 The influence on the immunomodulatory effects of dying and dead cells of Annexin V. J Leukoc Biol 2006 0.96
20 Remission of invasive, cancer stem-like glioblastoma xenografts using lentiviral vector-mediated suicide gene therapy. PLoS One 2009 0.96
21 Signal peptide requirements for lymphocytic choriomeningitis virus glycoprotein C maturation and virus infectivity. J Virol 2007 0.93
22 Mutations in gp120 contribute to the resistance of human immunodeficiency virus type 1 to membrane-anchored C-peptide maC46. J Virol 2009 0.90
23 Stable expression of soluble therapeutic peptides in eukaryotic cells by multimerisation: application to the HIV-1 fusion inhibitory peptide C46. ChemMedChem 2006 0.88
24 Retroviral insertional mutagenesis can contribute to immortalization of mature T lymphocytes. Mol Med 2011 0.88
25 Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol 2007 0.88
26 Normal brain cells contribute to the bystander effect in suicide gene therapy of malignant glioma. Clin Cancer Res 2007 0.86
27 Protein scaffold and expression level determine antiviral activity of membrane-anchored antiviral peptides. Hum Gene Ther 2009 0.85
28 Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J Mol Med (Berl) 2011 0.85
29 TK.007: A novel, codon-optimized HSVtk(A168H) mutant for suicide gene therapy. Hum Gene Ther 2010 0.84
30 Complement opsonization enhances friend virus infection of B cells and thereby amplifies the virus-specific CD8+ T cell response. J Virol 2010 0.83
31 Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy. J Mol Med (Berl) 2012 0.83
32 VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. J Virol 2014 0.83
33 Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection. Mol Ther 2011 0.83
34 Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol Ther 2013 0.82
35 A retroviral packaging cell line for pseudotype vectors based on glioma-infiltrating progenitor cells. J Gene Med 2007 0.79
36 T cell culture for gammaretroviral transfer. Methods Mol Biol 2009 0.79
37 A novel real-time CTL assay to measure designer T-cell function against HIV Env(+) cells. J Med Primatol 2014 0.78
38 Simplified generation of high-titer retrovirus producer cells for clinically relevant retroviral vectors by reversible inclusion of a lox-P-flanked marker gene. Mol Ther 2004 0.78
39 Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res 2007 0.78
40 Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses. PLoS One 2012 0.78
41 Comparison of three humanized mouse models for adoptive T cell transfer. J Gene Med 2012 0.76
42 A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity. Antimicrob Agents Chemother 2012 0.76
43 Cell and virus genetics at the roots of gene therapy, retrovirology, and hematopoietic stem cell biology: Wolfram Ostertag (1937-2010). Hum Gene Ther 2010 0.75
44 C peptides as entry inhibitors for gene therapy. Adv Exp Med Biol 2015 0.75